352P Impact of novel agent therapy on survival of patients with advanced non-small cell lung cancer in Lebanon

Abstract

In Lebanon, lung cancer (LC) ranks second in incidence (12.1%) and first in mortality (19.3%).Recent advances in molecular biology has improve survival of patients with lung cancer worldwide. Georgraphic variation in the molecular and biologic characteristics of LC will result in different outcomes of novel agent therapy across different regions. EGFR is found in 15-20% in the Western population, 50% in the Asians and 15.6% in the Lebanese population. ALK rearrangement is found in almost 5% of the Western patients and only 1.9% in the Lebanese population.The PDL-1 expression ranges from 24 to 60% in NSCLC worldwide and 61.7% in Lebanon.